Dimensional Fund Advisors LP Decreases Stock Position in Immunome, Inc. $IMNM

Key Points

• Dimensional Fund Advisors cut its Immunome stake by 89.4% in the first quarter, selling 282,975 shares and retaining 33,408 shares worth approximately $731,000. Institutional investors collectively own 44.58% of the company.
• Immunome reported a quarterly loss of $0.65 per share, missing the $0.51 consensus estimate, while analysts expect a full-year loss of $2.30 per share. Insiders have also sold 682,310 shares worth $15.7 million over the past 90 days.
• Despite ongoing losses, analysts remain broadly positive, with 12 Buy ratings, one Sell rating, and a consensus price target of $34.64 versus the stock’s $27.20 opening price. Investors are watching the FDA review of varegacestat and expected 2026 data from Immunome’s IM-1021 program.

Dimensional Fund Advisors LP cut its holdings in Immunome, Inc. (NASDAQ:IMNM - Free Report) by 89.4% in the first quarter, according to the company in its most recent disclosure with the SEC. The fund owned 33,408 shares of the company's stock after selling 282,975 shares during the quarter. Dimensional Fund Advisors LP's holdings in Immunome were worth $731,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in IMNM. KBC Group NV purchased a new position in shares of Immunome in the 1st quarter valued at approximately $60,000. BNP Paribas Financial Markets boosted its stake in Immunome by 81.8% in the 2nd quarter. BNP Paribas Financial Markets now owns 6,464 shares of the company's stock worth $60,000 after purchasing an additional 2,909 shares in the last quarter. Strs Ohio purchased a new stake in Immunome during the 4th quarter worth approximately $64,000. Tower Research Capital LLC TRC grew its position in Immunome by 121.2% during the 2nd quarter. Tower Research Capital LLC TRC now owns 6,938 shares of the company's stock worth $65,000 after purchasing an additional 3,802 shares during the last quarter. Finally, Russell Investments Group Ltd. acquired a new position in Immunome during the 3rd quarter valued at approximately $76,000. Institutional investors and hedge funds own 44.58% of the company's stock.

Immunome Stock Performance

NASDAQ:IMNM opened at $27.20 on Friday. The firm's fifty day moving average is $22.20 and its two-hundred day moving average is $22.24. The firm has a market cap of $3.09 billion, a price-to-earnings ratio of -10.75 and a beta of 2.08. Immunome, Inc. has a one year low of $8.66 and a one year high of $28.62.

Immunome (NASDAQ:IMNM - Get Free Report) last released its quarterly earnings data on Tuesday, August 11th. The company reported ($0.65) earnings per share for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.14). As a group, equities research analysts predict that Immunome, Inc. will post -2.3 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, insider Kinney Horn sold 90,616 shares of the firm's stock in a transaction that occurred on Tuesday, August 4th. The shares were sold at an average price of $25.09, for a total transaction of $2,273,555.44. Following the sale, the insider owned 50,366 shares of the company's stock, valued at $1,263,682.94. This trade represents a 64.27% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Max Rosett sold 60,000 shares of the firm's stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $18.23, for a total transaction of $1,093,800.00. Following the sale, the chief financial officer directly owned 54,037 shares in the company, valued at $985,094.51. The trade was a 52.61% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 682,310 shares of company stock valued at $15,675,566 in the last ninety days. Insiders own 7.21% of the company's stock.

Immunome News Roundup

Here are the key news stories impacting Immunome this week:

• Positive Sentiment: Investors remain focused on the FDA’s acceptance of Immunome’s varegacestat NDA and an April 2027 PDUFA decision date. The company also expects initial 2026 data from its Phase 1 IM-1021 ROR1 antibody-drug conjugate program, providing potential catalysts for the stock. Immunome catalysts and Strong Buy analysis
• Positive Sentiment: HC Wainwright maintained a Buy rating and projects a potential transition to profitability over the longer term, forecasting positive EPS of $0.40 in fiscal 2029 and $1.08 in fiscal 2030. These estimates support the longer-term investment case despite current losses.
• Neutral Sentiment: Director Isaac Barchas sold shares under a pre-arranged Rule 10b5-1 plan, including 98,712 shares from August 10–12 for roughly $2.6 million. The planned nature of the transactions makes them a less definitive signal about management’s current outlook, although the sales may weigh on sentiment. Immunome director insider sales SEC filing
• Negative Sentiment: Immunome reported a quarterly loss of $0.65 per share, wider than the consensus loss of $0.51. The earnings miss triggered a recent gap lower and highlights continued cash-burn and execution risks for the clinical-stage biotechnology company. Immunome shares gap down after earnings miss
• Negative Sentiment: HC Wainwright reduced its EPS forecasts for the near and medium term: Q3 2026 to $(0.65) from $(0.51), Q4 to $(0.68) from $(0.53), fiscal 2026 to $(2.45) from $(1.99), and fiscal 2027 to $(2.11) from $(1.72). The cuts suggest slower progress toward profitability, even though the firm retained its Buy rating.

Analysts Set New Price Targets

A number of research firms have issued reports on IMNM. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Immunome in a report on Friday, July 17th. Citigroup reissued a "buy" rating on shares of Immunome in a report on Thursday, July 9th. Truist Financial upped their target price on Immunome from $37.00 to $38.00 and gave the company a "buy" rating in a research report on Wednesday. HC Wainwright restated a "buy" rating on shares of Immunome in a research note on Thursday, July 9th. Finally, Wall Street Zen cut Immunome from a "sell" rating to a "strong sell" rating in a research report on Saturday. Twelve analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $34.64.

Immunome Profile

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome's approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company's lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.

Want to see what other hedge funds are holding IMNM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Immunome, Inc. (NASDAQ:IMNM - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source